Drug-Related Side Effects and Adverse Reactions
-
Subject Areas on Research
-
"If I'm better than average, then I'm ok?": Comparative information influences beliefs about risk and benefits.
-
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
-
A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials.
-
A clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF): design and rationale.
-
A comparison of the efficacy and safety of iopamidol-370 and iodixanol-320 in patients undergoing multidetector-row computed tomography.
-
A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer.
-
A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
-
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
-
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
-
A pre-marketing ALT signal predicts post-marketing liver safety.
-
A prospective study of the epidemiology of adverse drug reactions in pediatric hematology and oncology patients.
-
A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
-
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
-
A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy.
-
A safe practice standard for barcode technology.
-
AKI in Children Hospitalized with Nephrotic Syndrome.
-
Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
-
Achieving the goals of effective, safe, and individualized cancer care.
-
Adverse Effects of Hypnotic Medications.
-
Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
-
Adverse Effects of Statins.
-
Adverse drug events in high risk older outpatients.
-
Adverse drug reaction risk factors in older outpatients.
-
Adverse drug reactions.
-
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
-
Adverse events after discontinuing medications in elderly outpatients.
-
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
-
Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.
-
Alternate methods of framing information about medication side effects: incremental risk versus total risk of occurrence.
-
Alzheimer's disease: a study of epidemiological aspects.
-
Amiodarone and cyclophosphamide: potential for enhanced lung toxicity.
-
An observational study on the epidemiological and mycological profile of Candidemia in ICU patients.
-
Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP).
-
Aprotinin versus tranexamic acid: the controversy continues.
-
Aromatase Inhibitor Symptom Management Practices: A Retrospective Study.
-
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
-
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
-
Association of adverse drug reactions with drug-drug and drug-disease interactions in frail older outpatients.
-
Attention as a target of intoxication: insights and methods from studies of drug abuse.
-
Automated support for pharmacovigilance: a proposed system.
-
Basic and clinical studies of pharmacologic effects on recovery from brain injury.
-
Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.
-
Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With Hypertension.
-
Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.
-
Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
-
Bridging studies in clinical development.
-
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
-
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
-
Cefepime and Ceftazidime Safety in Hospitalized Infants.
-
Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020.
-
Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
-
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.
-
Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.
-
Clinically important drug-disease interactions and their prevalence in older adults.
-
Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.
-
Cognitive Aging: What We Fear and What We Know.
-
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
-
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
-
Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators.
-
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
-
Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.
-
Comparison of methods for detecting potential adverse drug events in frail elderly inpatients and outpatients.
-
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
-
Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer.
-
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.
-
Considerations of pharmacogenetic testing in children.
-
Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
-
Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.
-
Defining drinking water metal contaminant mixture risk by coupling zebrafish behavioral analysis with citizen science.
-
Deprescribing in Older Adults With Cardiovascular Disease.
-
Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
-
Design, implementation and evaluation of a clinical decision support system to prevent adverse drug events.
-
Development and validation of XML-based calculations within order sets.
-
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer.
-
Dialogue with patient care organizations.
-
Do geriatric conditions increase risk of adverse drug reactions in ambulatory elders? Results from the VA GEM Drug Study.
-
Do we need to adjudicate major clinical events?
-
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
-
Drug-drug interactions in older adults: which ones matter?
-
Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval.
-
Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al.
-
Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.
-
Effect of bar-code technology on the incidence of medication dispensing errors and potential adverse drug events in a hospital pharmacy.
-
Effect of bar-code technology on the safety of medication administration.
-
Effectiveness of a barcode medication administration system in reducing preventable adverse drug events in a neonatal intensive care unit: a prospective cohort study.
-
Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review.
-
Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy.
-
Effects of an education program for community pharmacists on detecting drug-related problems in elderly patients.
-
Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly.
-
Effects of selected pharmaceutically active compounds on treatment performance in sequencing batch reactors mimicking wastewater treatment plants operations.
-
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
-
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
-
Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis.
-
Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
-
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
-
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
-
Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
-
Errors associated with outpatient computerized prescribing systems.
-
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
-
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
-
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
-
Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
-
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance).
-
Frequency of high-risk use of QT-prolonging medications.
-
Fundamentals of Clinical Pharmacology With Application for Pregnant Women.
-
Fungal infections in transplant and oncology patients.
-
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
-
Glatiramer acetate: successful desensitization for treatment of multiple sclerosis.
-
HLA-B*35:01 and Green Tea-Induced Liver Injury.
-
Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.
-
Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.
-
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
-
Heterogeneity of toxicant response: sources of human variability.
-
High Prevalence of Fall-Related Medication Use in Older Veterans at Risk for Falls.
-
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma.
-
How important are drug-drug interactions to the health of older adults?
-
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
-
Iatrogenic lesions of soft tissue and bone.
-
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
-
Identifying genomic and developmental causes of adverse drug reactions in children.
-
Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children?
-
Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.
-
Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals.
-
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
-
Impact of inappropriate drug use on health services utilization among representative older community-dwelling residents.
-
Implementation of a smart pump champions program to decrease potential patient harm.
-
Implications of pharmacogenomics for drug development and clinical practice.
-
Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting.
-
Inappropriate medication use among frail elderly inpatients.
-
Inappropriate prescribing for elderly Americans in a large outpatient population.
-
Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes.
-
Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay.
-
Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial.
-
Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
-
Introduction to the special issue on emerging high throughput and complementary model screens for neurotoxicology.
-
Is There a Space-Based Technology Solution to Problems with Preclinical Drug Toxicity Testing?
-
Is This a 737 Max Moment for Brolucizumab?
-
Is primary care ready for pharmacogenetics?
-
Isavuconazole for treatment of rare invasive fungal diseases.
-
JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
-
Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group.
-
Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning.
-
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
-
Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity.
-
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
-
Management of Immunotherapy-Related Toxicities, Version 1.2019.
-
Management of adverse events associated with idelalisib treatment: expert panel opinion.
-
Managing the risks of therapeutic products: proceedings of a workshop.
-
Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
-
Measuring High-Risk Patients' Preferences for Pharmacogenetic Testing to Reduce Severe Adverse Drug Reaction: A Discrete Choice Experiment.
-
Medical Marijuana Use in Older Adults.
-
Medication dispensing errors and potential adverse drug events before and after implementing bar code technology in the pharmacy.
-
Medication errors in hospitalized cardiovascular patients.
-
Medication use and control of urination among community-dwelling older adults.
-
Medications in neonatal resuscitation.
-
Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults.
-
Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods.
-
Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic.
-
Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
-
Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events.
-
Mining hidden knowledge for drug safety assessment: topic modeling of LiverTox as a case study.
-
Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.
-
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
-
Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement.
-
Monitoring liver safety in drug development: the GSK experience.
-
Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.
-
Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.
-
Multimodal representation learning for predicting molecule-disease relations.
-
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.
-
National Survey of Neonatal Intensive Care Unit Medication Safety Practices.
-
National surveillance of herbal dietary supplement exposures: the poison control center experience.
-
New precompetitive paradigms: focus on cardiac safety.
-
Non-genetic risk factors for holoprosencephaly.
-
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.
-
Nonrenal indications for continuous renal replacement therapy: A report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group.
-
Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development.
-
Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.
-
PCA safety data review after clinical decision support and smart pump technology implementation.
-
Parental misinterpretations of over-the-counter pediatric cough and cold medication labels.
-
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
-
Patient clustering with uncoded text in electronic medical records.
-
Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.
-
Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
-
Patient-reported and actionable safety events in CKD.
-
Pediatric post-marketing safety systems in North America: assessment of the current status.
-
Perspectives of COVID-19 vaccine-hesitant emergency department patients to inform messaging platforms to promote vaccine uptake.
-
Pharmaceuticals as antifoulants: concept and principles.
-
Pharmacogenetics of toxic epidermal necrolysis.
-
Pharmacogenomics of adverse drug reactions: implementing personalized medicine.
-
Pharmacokinetic studies in infants using minimal-risk study designs.
-
Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.
-
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
-
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.
-
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
-
Polypharmacy in patients with advanced cancer and the role of medication discontinuation.
-
Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.
-
Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.
-
Preference weights for chemotherapy side effects from the perspective of women with breast cancer.
-
Prescribing of potentially harmful drugs to patients admitted to hospital after head injury.
-
Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry.
-
Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
-
Prevalence and risk factors of dry eye syndrome in a United States veterans affairs population.
-
Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
-
Quality of life in ICON7: need for patients' perspectives.
-
Quality of pharmacotherapy and outcomes for older veterans discharged from the emergency department.
-
Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
-
Recent Literature Update on Medication Risk in Older Adults, 2015-2016.
-
Recent Literature on Medication Errors and Adverse Drug Events in Older Adults.
-
Reducing Adverse Drug Events: The Need to Rethink Outpatient Prescribing.
-
Reducing polypharmacy: evidence from a simple quality improvement initiative.
-
Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
-
Rejoinder to the discussion of "a Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons," by S. Dias and A. E. Ades.
-
Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review.
-
Reliability of a modified medication appropriateness index in ambulatory older persons.
-
Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.
-
Risk factors for reduced glomerular filtration rate in a Nicaraguan community affected by Mesoamerican nephropathy.
-
Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab.
-
Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
-
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
-
Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
-
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
-
Safety monitoring of drugs receiving pediatric marketing exclusivity.
-
Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections.
-
Safety of zoster vaccine in elderly adults following documented herpes zoster.
-
Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
-
Safety-focused medication therapy management: a randomized controlled trial.
-
Screening for Adverse Drug Reactions in Dementia Patients on Cholinesterase Inhibitor Therapy.
-
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
-
Self-rated global measure of the frequency, intensity, and burden of side effects.
-
Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.
-
Sharing adverse drug event data using business intelligence technology.
-
Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders.
-
Statistical methods for bridging studies.
-
Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
-
Sulfites in medicines.
-
Survey of US public attitudes toward pharmacogenetic testing.
-
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
-
Tailoring adverse drug event surveillance to the paediatric inpatient.
-
Testing gene-treatment interactions in pharmacogenetic studies.
-
The FDA Sentinel Initiative - An Evolving National Resource.
-
The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.
-
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
-
The OPTIMIZE patient- and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial.
-
The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both.
-
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
-
The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks.
-
The cardiac-sympathetic axis as a teratological model.
-
The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement.
-
Thermo-responsive systems for controlled drug delivery
-
Tolerability profile of the current antifungal armoury.
-
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
-
Triggering management for quality improvement.
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
-
Understanding Potential Drug Side Effects: Can We Translate Molecular Mechanisms to Clinical Applications?
-
Update of studies on drug-related problems in older adults.
-
Update on Medication Use Quality and Safety in Older Adults, 2017.
-
Update on maculopathy secondary to pentosan polysulfate toxicity.
-
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs.
-
Using lithium as a neuroprotective agent in patients with cancer.
-
Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
-
Using pharmacogenetics to improve drug safety and efficacy.
-
Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
-
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
-
What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?
-
What clinicians should know about the QT interval.
-
What types of inappropriate prescribing predict adverse drug reactions in older adults?
-
What we know and what we don't know about the perioperative use of methadone in children and adolescents.
-
Keywords of People